Food segment
Operating income improved significantly
-Introduced price hikes for mainstay products
Offset the increased raw material and energy costs
-Volume decline less than anticipated
-Company-wide cost reductions
-Sales of high value-added core products grew and thus the product mix improved.
-Feature on TV programs in Q4 lead to significant growth in functional yogurt and chocolate.
Pharmaceutical segment
Secure operating income of 10 billion yen, similar amount to FYE March 2015
Covered adverse effect of one-time licensing revenues from previous year
-Sales of REFLEX and other mainstay products and of generic drug grew.
-Sales of subsidiaries also contributed.
Medreich and those in Thailand and Indonesia
-Agrochemicals and veterinary drugs recovered to break-even.
-Worldwide cost reductions
-R&D and strategic investments for future growth
Operating income improved significantly
-Introduced price hikes for mainstay products
Offset the increased raw material and energy costs
-Volume decline less than anticipated
-Company-wide cost reductions
-Sales of high value-added core products grew and thus the product mix improved.
-Feature on TV programs in Q4 lead to significant growth in functional yogurt and chocolate.
Pharmaceutical segment
Secure operating income of 10 billion yen, similar amount to FYE March 2015
Covered adverse effect of one-time licensing revenues from previous year
-Sales of REFLEX and other mainstay products and of generic drug grew.
-Sales of subsidiaries also contributed.
Medreich and those in Thailand and Indonesia
-Agrochemicals and veterinary drugs recovered to break-even.
-Worldwide cost reductions
-R&D and strategic investments for future growth